A Multi-Center, Randomized Controlled Study to Investigate the Safety and Tolerability of IV Ferric Carboxy Maltose (FCM) vs Standard Medical Care in Treating Iron Deficiency Anemia in Chronic Kidney Disease Patients
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Ferric carboxymaltose (Primary)
- Indications Anaemia
- Focus Adverse reactions
- Sponsors American Regent; Luitpold Pharmaceuticals
Most Recent Events
- 26 Jun 2014 New trial record